Sturm, Ruger Feeling the Effects of Desperate Rivals
While demand has picked up, heavy promotional activity in the industry remains a headwind.
Repligen Signals Gene Therapy Strength With 2019 Earnings Report
Guidance for 2020 appears to have spooked investors, but the bioprocess leader is on a solid long-term trajectory.
McDonald's Serving Up Fast-Food-Scented Candles
The world's biggest restaurant chain's newest product lets consumers enjoy the smell of a Quarter Pounder without the calories.
The pizza joint benefited from third-party food delivery apps battling one another.
Lower demand for certain goods and product scarcity could create a push-pull effect on Social Security's inflationary tether.
A shaky 2019 concluded with a bang for the family steakhouse.
Consumers rejoice: Your digital movies may be safe after all.
The bigger radio-controlled toy even includes a broken window sticker, just like the truck Elon Musk revealed in November.
According to The American Diabetes Association, every $1 in $7 spent in healthcare is spent on diabetes or its complications. We look at three companies well-positioned to capture this market.
Sources are starting to name specific suitors and citing potential prices, which would suggest serious discussions.
The federal agency is concerned that the tobacco giant failed to adequately disclose the risk it was taking with investing in JUUL.
The marijuana company's shares dipped by 2% after Jefferies hit it with an underperform rating.
The bank will avoid criminal prosecution if it abides by the terms of the settlement.
Millions of patients who don't respond well enough to statins now have another affordable alternative.
The companies are the subject of several investigations by government agencies and regulators.
New Leaf Data Services is compiling the numbers from cannabis business entities in Canada.
These three metrics reveal the strength of the tech services organization's business model.
The company reported fourth-quarter results that came up short.
A clinical trial suggests the COPD drug reduces the risk of death compared to GSK's older treatment, but the agency has concerns about the study's design.
The email security expert posted strong earnings this week.
The Canadian mining company has hit a rough patch.
The company must also support research activities after being awarded Clinical Registrant status by the state.
The toy maker could really use a boost in sales from Baby Yoda merchandise.